FR18C1008I1 - - Google Patents

Info

Publication number
FR18C1008I1
FR18C1008I1 FR18C1008C FR18C1008I1 FR 18C1008 I1 FR18C1008 I1 FR 18C1008I1 FR 18C1008 C FR18C1008 C FR 18C1008C FR 18C1008 I1 FR18C1008 I1 FR 18C1008I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR18C1008(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR18C1008I1 publication Critical patent/FR18C1008I1/fr
Application granted granted Critical
Publication of FR18C1008I2 publication Critical patent/FR18C1008I2/en
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FR18C1008C 2004-12-22 2018-02-14 CLADRIBINE DOSAGE REGIMEN FOR THE TREATMENT OF MULTIPLE SCLEROSIS Active FR18C1008I2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
PCT/EP2005/056954 WO2006067141A1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis
EP05823474A EP1827461B1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Publications (2)

Publication Number Publication Date
FR18C1008I1 true FR18C1008I1 (en) 2018-03-30
FR18C1008I2 FR18C1008I2 (en) 2019-03-01

Family

ID=36227798

Family Applications (1)

Application Number Title Priority Date Filing Date
FR18C1008C Active FR18C1008I2 (en) 2004-12-22 2018-02-14 CLADRIBINE DOSAGE REGIMEN FOR THE TREATMENT OF MULTIPLE SCLEROSIS

Country Status (24)

Country Link
US (2) US7713947B2 (en)
EP (6) EP4070800A1 (en)
JP (7) JP5795456B2 (en)
KR (1) KR20070091662A (en)
AR (1) AR052830A1 (en)
AU (2) AU2005318190B2 (en)
BR (1) BRPI0517132B8 (en)
CA (2) CA3087419C (en)
CY (3) CY1112614T1 (en)
DK (2) DK2805723T3 (en)
EA (1) EA015799B1 (en)
ES (1) ES2921858T3 (en)
FR (1) FR18C1008I2 (en)
HR (1) HRP20120228T1 (en)
HU (2) HUE059133T2 (en)
IL (2) IL183930A0 (en)
LT (2) LT3332789T (en)
LU (1) LUC00064I2 (en)
MX (1) MX2007007610A (en)
NO (1) NO20073813L (en)
PL (3) PL2805723T3 (en)
SG (1) SG160391A1 (en)
SI (2) SI2805723T1 (en)
WO (1) WO2006067141A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2026832T3 (en) * 2006-05-24 2012-08-31 Merck Serono Sa Combination of interferon-beta and a cladribine regimen for treating multiple sclerosis
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) * 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
EP3713582A1 (en) * 2017-11-24 2020-09-30 Merck Patent GmbH Cladribine regimen for use intreating progressive forms of multiple sclerosis
GB2601786A (en) * 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
PL321431A1 (en) 1994-12-22 1997-12-08 Ortho Pharma Corp Soluble 2-chloro-2'deoxyadenosine compositions
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (en) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Use of treosulfan and derivatives thereof for the treatment of multiple sclerosis
JP4757632B2 (en) 2002-09-25 2011-08-24 ブリガム ヤング ユニバーシティー Method for preparing 2-chloro-2'-deoxyadenosine from 2'-deoxyguanosine
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
CA2515210A1 (en) * 2003-02-25 2004-09-10 Applied Research Systems Ars Holding N.V. Combined use of ribavirin and interferon beta in demyelinating diseases
CA2520522C (en) 2003-03-28 2012-05-29 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
BRPI0408848B8 (en) 2003-03-28 2021-07-27 Ares Trading Sa pharmaceutical compositions of complex cyclodextrin-cladribine complex, uses of said complex, as well as processes for its preparation
PL2026832T3 (en) * 2006-05-24 2012-08-31 Merck Serono Sa Combination of interferon-beta and a cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
US7713947B2 (en) 2010-05-11
JP2015180685A (en) 2015-10-15
NO20073813L (en) 2007-09-21
BRPI0517132A (en) 2008-09-30
LTC2805723I2 (en) 2022-04-25
AU2011200768A1 (en) 2011-03-17
CY2018006I1 (en) 2018-06-27
US20100203017A1 (en) 2010-08-12
EP2263678B1 (en) 2014-06-11
JP2008524313A (en) 2008-07-10
JP5908863B2 (en) 2016-04-26
CY1112614T1 (en) 2016-02-10
IL212421A (en) 2014-01-30
JP2013216664A (en) 2013-10-24
HUE059133T2 (en) 2022-10-28
SI2805723T1 (en) 2018-02-28
JP2017101061A (en) 2017-06-08
JP6092945B2 (en) 2017-03-08
JP5795456B2 (en) 2015-10-14
DK3332789T3 (en) 2022-07-11
EP2263678A2 (en) 2010-12-22
AU2011200768B2 (en) 2012-09-13
ES2921858T3 (en) 2022-09-01
US20090081163A1 (en) 2009-03-26
JP6430554B2 (en) 2018-11-28
LUC00064I2 (en) 2018-03-28
EA015799B1 (en) 2011-12-30
HRP20120228T1 (en) 2012-04-30
EP2275110A2 (en) 2011-01-19
EP2263678A3 (en) 2011-04-27
EP1827461B1 (en) 2012-02-29
CA3087419A1 (en) 2006-06-29
MX2007007610A (en) 2007-08-03
PL3332789T3 (en) 2022-08-22
EP4070800A1 (en) 2022-10-12
LTPA2018503I1 (en) 2018-03-12
EA200701221A1 (en) 2008-02-28
AU2005318190B2 (en) 2010-11-25
KR20070091662A (en) 2007-09-11
LUC00064I1 (en) 2018-02-14
EP2275110A3 (en) 2011-04-27
EP3332789B1 (en) 2022-04-06
DK2805723T3 (en) 2018-01-29
EP1827461A1 (en) 2007-09-05
JP6290962B2 (en) 2018-03-07
BRPI0517132B1 (en) 2020-02-18
JP2018165271A (en) 2018-10-25
IL212421A0 (en) 2011-06-30
EP2805723B1 (en) 2018-01-17
CA2588966A1 (en) 2006-06-29
WO2006067141A1 (en) 2006-06-29
PL2805723T3 (en) 2018-04-30
CY2018006I2 (en) 2018-06-27
AR052830A1 (en) 2007-04-04
US8377903B2 (en) 2013-02-19
CA2588966C (en) 2020-07-21
LT3332789T (en) 2022-07-25
SG160391A1 (en) 2010-04-29
BRPI0517132B8 (en) 2021-05-25
SI3332789T1 (en) 2022-08-31
CY1119790T1 (en) 2018-06-27
EP3332789A1 (en) 2018-06-13
JP2016138128A (en) 2016-08-04
FR18C1008I2 (en) 2019-03-01
JP2020193206A (en) 2020-12-03
PL1827461T3 (en) 2012-07-31
CA3087419C (en) 2023-03-07
EP2275110B1 (en) 2013-07-10
IL183930A0 (en) 2007-10-31
AU2005318190A1 (en) 2006-06-29
HUS1800009I1 (en) 2018-05-02
EP2805723A1 (en) 2014-11-26

Similar Documents

Publication Publication Date Title
BE2015C038I2 (en)
IN2014DN10707A (en)
BRPI0518216C1 (en)
BRPI0515516B8 (en)
BR122015024347A2 (en)
BRPI0508002A (en)
BR122018073034B8 (en)
BRPI0508029A (en)
BRPI0419105B8 (en)
BRPI0508026A (en)
BRPI0508033A (en)
CN300736035S (zh) 蒸汽发生器基座(1)
CN300736473S (zh) 洗手盆
CN300781624S (zh) 电视机
CN300781317S (zh) 叉车
CN300779224S (zh) 龙头
CN300775620S (zh) 太阳能逆变器
CN300765733S (zh) 瓶子
CN300736469S (zh) 净身盆
CN300729373S (zh) 包装盒(曲面的蛤壳式)
CN300731631S (zh) 衣架
CN300731632S (zh) 衣架
CN300732651S (zh) 起动器的主体
CN300734497S (zh) 旋转椅子
CN300764069S (zh) 便携式媒体播放机